Aurobindo Pharma unit gets US FDA Form 483 with 5 procedural observations

Regulatory & Legal View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.6%Reaction day

₹1192.00

prior close

₹1183.40

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.2%+1.3% vs market

Pharmaceuticals peers, median of 152sector-0.5%+2.0% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty Midcap 150 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.4

15m

+0.4

30m

+1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.6+0.2+1.3-0.5+2.0

Next day

+2.8+1.4+1.4+0.5+2.2

+2.7+2.2+0.5+1.0+1.7

+2.1+2.3-0.3+1.1+1.0

+1.8+1.8-0.1+0.9+0.8

+1.4+1.6-0.2+0.5+0.9

-0.1+1.0-1.1-0.3+0.1

15d

+0.3+0.6-0.4-0.4+0.6

-2.3+0.1-2.5-2.7+0.4

-2.0+1.4-3.4-2.4+0.4

+6.4-5.0+11.4-9.0+15.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

US FDA inspected Unit-IV of APL Healthcare, a wholly owned subsidiary of Aurobindo Pharma, in Andhra Pradesh from December 8 to 17, 2025. A Form 483 was issued with 5 procedural observations. The company says there is no impact on financials or operations and will respond within required timelines.

Likely market impact

Routine inspection with minor procedural observations; no immediate impact on finances or operations. Watch for company response.